Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Michael Friedlander
Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors
Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors Supplement 1. eTable 2. Electronic Database Questionnaire eTable 3. Second Primary Cancers eTable 4. Overview of Characteristics of BRCA1 and BRCA2 Pathogenic Variants Documented in Exceptional Responders eTable 5. Variant Characteristics for Exceptional Responders Compared to Those for PAOLA-1 Trial Participants eTable 6.
It's Virginia’s moment to accelerate momentum in biomedical R&D | Guest column
Colin wears a Star Wars cap as he plays soccer in his yard, his wide smile showing the familiar mix of baby and adult teeth that mark childhood milestones. But Colin’s story is anything but ordinary. At eight years old, he survived childhood leukemia thanks to an emerging treatment — Chimeric antigen receptor (CAR) T-cell therapy.
Friedlander: A smart investment for Southwest Virginia
When the General Assembly and governor approved $26.5 million to establish the Virginia Tech Patient Research Center at VTC, located in the Fralin Biomedical Research Institute at VTC on the health sciences and innovation campus in Roanoke, they made a strategic investment in the health and economic future of Southwest Virginia.
Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial | Nature Communications
Commentary: Researching ways to help those whose lives are touched by rare diseases
For the second year in a row, on the last day of February in downtown Roanoke, you might notice the top of the Wells Fargo Tower lit up with pink, green, purple and blue. We are shining a light on important but uncommon diseases in recognition of global Rare Disease Day with hues that represent the beauty and breadth of the lives of our friends and family members who may have a rare disease. Scientific advances have identified more than 10,000 rare diseases.
Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer - British Journal of Cancer
Abstract CA-125 alone is widely used to diagnose progressive disease (PD) in platinum-sensitive recurrent ovarian cancer (PSROC) on chemotherapy. However, there are increasing concerns regarding its accuracy. We assessed concordance between progression defined by CA-125 and RECIST using data from the CALYPSO trial. We computed concordance rates for PD by CA-125 and RECIST to determine the positive (PPV) and negative predictive values (NPV).
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial | British Journal of Cancer
Abstract Background The aim of this study was to investigate the antitumour activity, safety, and tolerability of pamiparib plus tislelizumab in patients with previously treated advanced solid tumours. Methods In this study, patients were enrolled into eight arms by tumour type. All received pamiparib 40 mg orally twice daily plus tislelizumab 200 mg intravenously every 3 weeks.
The missing link: Biotechnology labs in Roanoke – our next step in 'biology’s century'
When Virginia Agricultural and Mechanical College opened 150 years ago in Blacksburg, the land-grant university became a center of mechanized farming innovation. The Roanoke Hospital Association’s founding 123 years ago represented a modern railroad city’s response to treating the injured and ill.
Patients with rare diseases must not be forgotten
Tonight in Downtown Roanoke, you might notice the top of Wells Fargo Tower lit up with pink, green, purple and blue. We are shining a light on important but uncommon diseases in recognition of Rare Disease Day, which occurs annually on the last day of February. Scientific advances have identified more than 7,000 rare diseases. Each one affects less than 200,000 patients, but cumulatively they affect almost 10% of Americans, or more than 30 million people.
Risk of Peritoneal Cancer After Risk-Reducing Bilateral Salpingo-Oophorectomy for Women With Germline BRCA Pathogenic Variants: A Cause for Concern or Potentially Avoidable? | Journal of Clinical Oncology
Women who carry a germline BRCA1 or BRCA2 pathogenic variant (PV) have a high lifetime risk of epithelial ovarian cancer. The average cumulative risk by age 80 years is 44% for those with a BRCA1 PV and 17% for those with a BRCA2 PV, 1 compared with 1.3% for the general population. 2 Most are high-grade serous cancers that appear to originate, predominantly from serous tubal intraepithelial carcinoma (STIC), in the fimbria or distal third of the fallopian tube.
Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial - Jean-Pi
Introduction Germline mutations in breast cancer susceptibility genes gBRCA1 and gBRCA2 are estimated to occur in approximately 1–5% of all breast cancers.1 The BRCA1 and BRCA2 proteins function in the repair of double-stranded DNA breaks through homologous recombination.2 Therapeutic agents that inhibit DNA synthesis or repair mechanisms, including platinum-containing compounds and poly(adenosine diphosphate-ribose) polymerase inhibitors (PARPis), have shown efficacy for treating gBRCA1/2...
Friedlander: Fralin Institute success grew from partnerships, support
Friedlander: Fralin Institute success grew from partnerships, support Assistant Professor Shannon Farris peers into a microscope at the Fralin Biomedical Research Institute. Farris studies the molecular basis of memory and how it connects to dementia and other diseases.
Prognostic nomogram for progression-free survival in patients with BRCA mutations and platinum-sensitive recurrent ovarian cancer on maintenance olaparib therapy following response to chemotherapy
Highlights • The impact of maintenance PARPi on PFS in women with BRCA-mutant PSROC varies widely. • Our nomogram includes CA-125, PFI, measurable disease and prior platinum therapy. • Our nomogram and online tool demonstrates good discrimination and is well-calibrated. • Our nomogram can help to predict PFS and counsel patients prior to olaparib therapy.
Reporting the trajectories of adverse events over the entire treatment course in patients with recurrent platinum-sensitive ovarian cancer treated with platinum-based combination chemotherapy regimens: A graphical approach to trial adverse event reporting
Highlights • Clinical trials seldom report timing, duration and recurrence of adverse events. • Duration and recurrence of adverse events are crucial in clinical decision making. • A novel method and illustration are used to describe adverse event trajectories. • Methods use readily available data and could be reported in all clinical trials. • Methods are applicable to any new or emerging cancer treatments.
Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial
Summary Background In the phase 3 SOLO1 trial, maintenance olaparib provided a significant progression-free survival benefit versus placebo in patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation in response after platinum-based chemotherapy. We analysed health-related quality of life (HRQOL) and patient-centred outcomes in SOLO1, and the effect of radiological disease progression on health status.
Molecular and clinical predictors of improvement in progression‐free survival with maintenance PARP inhibitor therapy in women with platinum‐sensitive, recurrent ovarian cancer: A meta‐analysis
Original Article Chee Khoon Lee PhD Corresponding Author chee.lee@ctc.usyd.edu.au orcid.org/0000-0003-2955-9820 National Health and Medical Research Council Clinical Trials Center, University of Sydney, Sydney, New South Wales, Australia Australia New Zealand Gynecological Oncology Group, Camperdown, New South Wales, Australia Corresponding Author: Chee Khoon Lee, PhD, NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia (chee.lee@ctc.usyd.edu.au).
Friedlander: What is a future worth?
Friedlander: What is a future worth? During February, Americans continued to face the devastation of the COVID-19 pandemic, and we celebrated heart month. The Centers for Disease Control and Prevention (CDC) calculates that each day in February, 3,049 Americans died due to COVID-19, while an additional 2,068 died from cardiovascular disease. And we are learning more about the connections between COVID-19 and heart disease.
Pre- and Post-Diagnosis Diet Quality and Ovarian Cancer Survival
Null Results in Brief Ruqaiya M. Al Ramadhani, Christina M. Nagle, Torukiri I. Ibiebele, Peter Grant, Michael Friedlander, Anna DeFazio and Penelope M. Webb; the Ovarian Cancer Prognosis and Lifestyle Study Group DOI: 10.1158/1055-9965.EPI-20-1036 Published January 2021 This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Pre- and post-diagnosis diet quality and ovarian cancer survival.
Null Results in Brief Ruqaiya M Al Ramadhani, Christina M. Nagle, Torukiri I Ibiebele, Peter Grant, Michael Friedlander, Anna DeFazio and Penelope M. Webb DOI: 10.1158/1055-9965.EPI-20-1036 Abstract Background: Prior studies evaluating diet quality in relation to ovarian cancer survival are sparse, and to date none have assessed diet quality or diet quality change after diagnosis.
Concordance between CA-125 and RECIST progression in patients with germline BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2 trial with olaparib as maintenance therapy after response to chemotherapy
Highlights • There is poor concordance between CA-125 non-PD and RECIST progression. • Half the patients without CA-125 PD had RECIST PD, most had normal CA-125 levels. • CT imaging to be considered as part of follow-up rather than relying on CA-125 alone. Abstract Background Limited evidence exists to support CA-125 as a valid surrogate biomarker for progression in patients with ovarian cancer on maintenance PARP inhibitor (PARPi) therapy.
Friedlander: Roanoke can do better
By Michael Friedlander Friedlander is founding executive director, Fralin Biomedical Research Institute at VTC; Virginia Tech vice president for Health Sciences and Technology; Senior dean for Research, Virginia Tech Carilion School of Medicine; Virginia Tech professor of Biological Sciences, of Biomedical Engineering and of Psychiatry and Behavioral Medicine. As within any healthy family, it is important to honestly share the good and the bad.
That Communication Thing: A Fine Art
That Communication Thing: A Fine Art January 12, 2015 Hosted by Michael Friedlander [Download MP3]
[itunes]
[Bookmark Episode] Guest Information Note:Scroll left for more guests Episode Description Communication lies at the center of everything we do, both professionally and personally...
That Motivation Thing: Getting the best out of people
That Motivation Thing: Getting the best out of people January 19, 2015 Hosted by Michael Friedlander [Download MP3]
[itunes]
[Bookmark Episode] Guest Information Note:Scroll left for more guests Episode Description Amongst the greatest challenges we face in realizing our dreams is to motivate those around us to help us accomplish whatever we are setting out to do.
That Corporate Responsibility Thing: Challenging the Executive Mind
That Corporate Responsibility Thing: Challenging the Executive Mind February 2, 2015 Hosted by Michael Friedlander [Download MP3]
[itunes]
[Bookmark Episode] Guest Information Note:Scroll left for more guests Episode Description Implementing a corporate responsibility program requires executives to embrace fundamental ethical concepts and to lead by example. They have to walk-the-walk as they talk-the-talk. Similarly, those they lead just buy into the goals and importance of the program.
That Ethics Thing: Going beyond those beautifully written codes
That Ethics Thing: Going beyond those beautifully written codes January 26, 2015 Hosted by Michael Friedlander [Download MP3]
[itunes]
[Bookmark Episode] Guest Information Note:Scroll left for more guests Episode Description Whether we are running a large or small business or whether we are dreaming of climbing a corporate ladder, we'll always find ourselves being confronted with difficult ethical questions. Sometimes, but not often, the answers might be find in a Code of Ethics.
That Yoga and Meditation Thing: A Key To The Door …
That Yoga and Meditation Thing: A Key To The Door … January 5, 2015 Hosted by Michael Friedlander [Download MP3] [itunes] [Bookmark Episode] Guest Information Note:Scroll left for more guests Episode Description There are many who rely on meditation and yoga to provide them with the balance and tranquility they need to make wise decisions… There are many who believe that they are indispensible activities for realizing one’s dreams and achieving one’s potential… Our guest, Kristen Eykel, has...
That Sustainability Thing: Learning from the past
That Sustainability Thing: Learning from the past December 15, 2014 Hosted by Michael Friedlander [Download MP3]
[itunes]
[Bookmark Episode] Guest Information Note:Scroll left for more guests Episode Description For some, the sustainability movement is something relatively new. They associate it with clean technology, new solar panel technologies and modern wind farms.
That Curiosity Thing: How a dose of ethics might avoid a sense of deja vu
That Curiosity Thing: How a dose of ethics might avoid a sense of deja vu February 9, 2015 Hosted by Michael Friedlander [Download MP3]
[itunes]
[Bookmark Episode] Guest Information Note:Scroll left for more guests Episode Description In this episode, we discuss with Professor Diane Swanson and Steve Burrows, CBE, the lessons we might have learned from the Enron, Madoff and Sub-Prime Mortgage adventures.
That Crisis Thing: Facing It With Dignity
That Crisis Thing: Facing It With Dignity December 29, 2014 Hosted by Michael Friedlander [Download MP3]
[itunes]
[Bookmark Episode] Guest Information Note:Scroll left for more guests Episode Description The Chinese word for “crisis” is made up of two Chinese characters. The first is “danger.” The second also offers an “opportunity.” Many see a crisis only in the context of danger. In doing so, many show their worst personality traits as they react to the perceived danger.
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial
Summary Background Rationale exists for combined treatment with immune checkpoint inhibitors and poly (ADP-ribose) polymerase (PARP) inhibitors in a variety of solid tumours. This study aimed to investigate the safety and antitumour effects of pamiparib, an oral PARP 1/2 inhibitor, combined with tislelizumab, a humanised anti-PD-1 monoclonal antibody, in patients with advanced solid tumours and to determine the optimum doses for further evaluation.
Development and validation of a prognostic nomogram for overall survival in patients with platinum-resistant ovarian cancer treated with chemotherapy
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Fig. 1 Nomograms to predict the probability of 1-year OS. Points were assigned for performance status, ascites, size of largest tumour detected on imaging, CA-125, PFI and platinum resistance, by drawing a line upward from the corresponding values to the ‘Points’ line.
Friedlander: Investing in and paying for biomedical research - economic dividends
By Michael J. Friedlander| Friedlander is Founding Executive Director, Fralin Biomedical Research Institute at VTC; Virginia Tech Vice President for Health Sciences and Technology; Senior Dean for Research, Virginia Tech Carilion School of Medicine; Virginia Tech Professor of Biological Sciences, of Biomedical Engineering and of Psychiatry and Behavioral Medicine.
Friedlander: Fralin Biomedical Research Institute scientists target critical medical needs
By Michael J. Friedlander Friedlander is Founding Executive Director, Fralin Biomedical Research Institute at VTC; Virginia Tech Vice President for Health Sciences and Technology; Senior Dean for Research, Virginia Tech Carilion School of Medicine; Virginia Tech Professor of Biological Sciences, of Biomedical Engineering and of Psychiatry and Behavioral Medicine.
Friedlander: Fralin Institute creates an influx of talent to the community
By Michael J. Friedlander Friedlander is Founding Executive Director, Fralin Biomedical Research Institute at VTC; Virginia Tech Vice President for Health Sciences and Technology; Senior Dean for Research, Virginia Tech Carilion School of Medicine; Virginia Tech Professor of Biological Sciences, of Biomedical Engineering and of Psychiatry and Behavioral Medicine.
Friedlander: What is a biomedical research institute and why does it matter to Roanoke?
By Michael J. Friedlander Friedlander is the founding executive director of Fralin Biomedical Research Institute at VTC; Virginia Tech vice president for Health Sciences and Technology; senior dean for research, Virginia Tech Carilion School of Medicine; Virginia Tech professor of biological sciences, of biomedical engineering and of psychiatry and behavioral Medicine. The last decade was an exciting chapter in the history of Roanoke.
Friedlander: The importance of I-81 improvements for the future of the growing Roanoke-based biomedical research enterprise
By Michael Friedlander Friedlander is Executive Director, Fralin Biomedical Research Institute at VTC; Virginia Tech Vice President for Health Sciences and Technology; Senior Dean for Research, Virginia Tech Carilion School of Medicine; Virginia Tech Professor of Biological Sciences, of Biomedical Engineering and of Psychiatry and Behavioral Medicine. I have been closely following the discussions around Interstate 81 over the last several months.
Friedlander: The science of early childhood success
In a climate where consensus on policy issues can be elusive, the importance of high quality early childhood development programs that are based on solid scientific foundations should unite us across the political spectrum. The reason is simple. The quality of a child’s early life experiences is one of the most impactful ways to set young people on a positive trajectory of learning, growing, and succeeding.
Long-term efficacy, tolerability and overall survival in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer treated with maintenance olaparib capsules following response to chemotherapy
We report the final analyses of long-term efficacy and tolerability data from Study 19, a Phase II trial assessing olaparib maintenance monotherapy (400 mg bid, capsule formulation) in patients with platinum-sensitive, recurrent high-grade serous ovarian cancer in response to their most recent platinum-based chemotherapy regimen, representing the longest follow-up from any PARP inhibitor trial reported.
Cancer of the ovary, fallopian tube, and peritoneum
Abstract The Gynecologic Oncology Committee of FIGO in 2014 revised the staging of ovarian cancer, incorporating ovarian, fallopian tube, and peritoneal cancer into the same system. Most of these malignancies are high‐grade serous carcinomas (HGSC). Stage IC is now divided into three categories: IC1 (surgical spill); IC2 (capsule ruptured before surgery or tumor on ovarian or fallopian tube surface); and IC3 (malignant cells in the ascites or peritoneal washings).
Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised tria
In the phase 3 SOLO2 trial (ENGOT Ov-21), maintenance therapy with olaparib tablets significantly prolonged progression-free survival (primary endpoint) compared with placebo in patients with a germline BRCA1 or BRCA2 ( BRCA1/2) mutation and platinum-sensitive, relapsed ovarian cancer who had received two or more lines of previous chemotherapy. The most common subjective adverse effects included fatigue, nausea, and vomiting, which were typically low grade and self-limiting.
A Systematic Review of Health‐Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve
Epithelial ovarian cancer (OC) remains a significant cause of morbidity and mortality for women worldwide. Patients may experience a multitude of disease? and treatment?related symptoms that can impact quality of life (QOL) and should be measured and reported in clinical trials. This systematic review investigated the adequacy of reporting of QOL in randomized phase III trials in OC in both the first?line and recurrent disease setting.
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale, Future Oncology, Future Medicine
Veliparib is an orally administered poly(ADP-ribose) polymerase inhibitor that is being studied in Phase I–III clinical trials, including Phase III studies in non-small-cell lung cancer, ovarian cancer and breast cancer. Tumor cells with deleterious BRCA1 or BRCA2 mutations are deficient in homologous recombination DNA repair and are intrinsically sensitive to platinum therapy and poly(ADP-ribose) polymerase inhibitors.
Machine Learning + Satellite Pics = Knowledge
Stanford University researchers calculated poverty down to the village level in five African countries - without using any poverty data.
Speak UP: Raising the Voices of Women - Toastmasters District 46
1- Go to www.zoom.us. 2- In the upper right of the screen it says Join A Meeting. If you are on a mobile device it will ask you to download the free app. 3- Click on Join A Meeting. 4- If prompted click OK to connect. 5 – Enter Meeting ID 790 261 5250. 6 – You will come up live on video camera to join the meeting. 7 – In the lower left of your screen will be the Tool Bar for Mute or Video Off if you would prefer.
Philanthropy Will Benefit From Buoyant Auckland Property Market
The family is well known for its philanthropy to both the arts and science and, donated in the name of Michael’s late wife the Harriet Friedlander Scholarship Trust is one of the most generous residencies offered to New Zealand artists. Mr Friedlander is also a benefactor of the Auckland Theatre Company and the Friedlander Foundation donates to stem cell research.
CGC and Boom! Announce New George Perez Label
CGC and Boom! Studios have teamed up with George Perez to create the first-ever custom art CGC label. Perez hand-sketched characters from the Sirens series for a certification label that will be available just in time for encapsulation with George Perez’s Sirens #4, scheduled for release by Boom! Studios on July 8 at San Diego Comic-Con. Certified Guaranty Company (CGC) and Boom! Studios have teamed up with George Perez to create the first-ever custom art CGC label.
A life of genius and tragedy – Physics World
American Prometheus: The Triumph and Tragedy of J Robert Oppenheimer Kai Bird and Martin J Sherwin 2005 Knopf 721pp $35.00hb Most young people today will associate the name J Robert Oppenheimer – if they recognize it at all – with the Manhattan Project and the atomic bombs that were dropped on Japan in the last days of the Second World War. However, those of us who lived through those momentous times will remember much more about this great physicist.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Michael
Contact Michael, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack